moneyheap
FMC · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is FMC Corporation (FMC) stock moving?
FMC's Q3 2026 report on Oct 29 was a sharp negative. Revenue was $106M against $542M a year earlier, after a roughly $639M hit from commercial actions, and adjusted EPS of $(4.41) missed the $0.10 estimate. Management cut FY2026 sales guidance to $2.75B-$2.85B from $3.50B-$3.70B, guided Q4 adjusted EPS to $0.56-$0.70, and now expects full-year free cash flow of negative $350M to negative $150M. Benzinga also reports negative stockholders' equity of $(19.4)M. The stock rose from about $4.75 to a $6.20 close on Oct 30, on 17.7M shares versus a typical 5-7M, peaked at $6.50 on Nov 2, and has since slid to $5.64 on Nov 10, with volume back near 5M shares. Every analyst action in the news set was a target cut with a neutral rating (UBS $6.50, RBC $7, Citi Hold $7, Morgan Stanley $8, Jefferies Hold). The price sits below all of these targets. Supportive points are the Tessenderlo stake bought at $13.30 (closed Sept 23), the Oct 15 credit amendment directing India sale proceeds to debt repayment, and management's view that 2027 will improve and 2028 will show stronger growth. Those recovery claims are not yet testable, so the near-term picture is weighted to the downside.
News behind the analysis
- FMC Corporation Reports Third-Quarter 2026 Results and Revised Fourth-Quarter OutlookQ3 revenue was $106M, down $436M year over year, including a roughly $639M hit from commercial actions. GAAP net loss was $2.07B, and the company lowered its Q4 outlook.
- FMC Lowers FY2026 Adj EPS Guidance from $1.19-$1.49 to $(3.66)-$(3.50) vs $1.26 Est; Lowers FY2026 Sales Guidance from $3.500B-$3.700B to $2.750B-$2.850B vs $3.511B EstFull-year 2026 adjusted EPS guidance moved to a loss of $3.50 to $3.66, and sales guidance was cut to $2.75B-$2.85B, well below the prior $3.50B-$3.70B range.
- FMC Q3 Adj. EPS $(4.41) Misses $0.10 Estimate, Sales $105.900M Miss $859.594M EstimateAdjusted third-quarter EPS of $(4.41) missed the $0.10 estimate, and reported sales of $105.9M came in far below the $859.6M consensus.
- FMC Lowers Q4 Adj EPS Guidance from $1.09-$1.33 to $0.56-$0.70 vs $1.06 Est; Lowers Q4 Sales Guidance from $1.060B-$1.200B to $1.040B-$1.140B vs $1.100B EstQ4 adjusted EPS guidance was cut to $0.56-$0.70, and Q4 sales guidance was reduced to $1.04B-$1.14B.
- UBS Adjusts FMC Corporation Price Target to $6.50UBS cut its FMC price target from $10 to $6.50 and kept a Neutral rating.
- Citi Maintains Hold Rating on FMC Corporation, Raises Price Target to $7Citi kept its Hold rating and raised its FMC price target from $6 to $7 after the third-quarter report.
- Morgan Stanley Adjusts Price Target on FMC CorporationMorgan Stanley kept its Equal-Weight rating and lowered its FMC price target from $12 to $8.
- RBC Capital Markets Adjusts FMC Corporation Price TargetRBC cut its FMC price target from $9 to $7 and kept a Sector Perform rating.
- Jefferies Initiates Coverage on FMC CorporationJefferies initiated coverage of FMC with a Hold rating, citing concerns about pricing headwinds.
- FMC Q3 2026 Earnings Call TranscriptThe transcript of the third-quarter 2026 earnings call, held the same week as the results release, is available for review.
About FMC Corporation
FMC is a Philadelphia-based company that makes crop-protection products: insecticides, herbicides and fungicides that farmers use to protect their crops. Its best-known insecticide, Rynaxypyr (chlorantraniliprole), has lost patent protection, and FMC is trying to grow newer active ingredients such as Isoflex, fluindapyr and Dodhylex while it pays down debt and explores strategic options, including a possible sale of the company, which it announced in early 2026.
How it makes money
FMC sells branded crop-protection chemicals to distributors, retailers and, increasingly, directly to growers in North America, Latin America (especially Brazil), Europe and Asia. It also supplies diamide active ingredients to partner companies. Insecticides, led by the diamide franchise, have historically been the largest share of sales, with herbicides and fungicides making up the rest. Full-year 2026 revenue was guided at roughly $3.5–3.7 billion before third-quarter actions to reduce how much FMC inventory distributors were holding. Those actions cut Q3 2026 revenue to about $106 million.
What usually moves FMC
- Generic competition and price erosion after Rynaxypyr patent expiry
- Distributor inventory levels and farmer demand, especially in Brazil
- Outcome of the strategic review and potential sale
- Debt reduction and free cash flow
- Uptake of new active ingredients